IncellDx Files Patents for Two Distinct Algorithms for COVID Long-Hauler Index and Active COVID-19 Severity Score; Algorithms Built on Tailored Panel of Cytokines & Chemokines Specific for Cytokine Storm Conditions and Chronic COVID Long-Haulers

On February 3, 2021, IncellDx, a leading precision medicine diagnostics company, announced that it had filed patents for algorithms identifying immunologic profiles unique to COVID long-haulers and patients with severe COVID. IncellDx has developed and patented two distinct algorithms using machine learning, built on a tailored panel of cytokines and chemokines specific for abnormalities in cytokine storm conditions and in chronic COVID patients (often referred to as COVID "long-haulers"). These have been submitted for publication (pre-print available through BioRxiv The preprint is titled “Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning.” The first algorithm generates a severity score based on analysis of hundreds of COVID-19 patients spanning the spectrum of disease severity from mild to critical. The second algorithm derived from the same cytokine/chemokine immune panel, demonstrates that the immunology of long-haulers is distinct from active COVID-19. This objective algorithm offers the opportunity for precision medicine to be used by physicians as a guide in the care of COVID-19 patients. Bruce Patterson, MD, CEO of IncellDx, commented that "Since the beginning of the COVID-19 pandemic, IncellDx has led the way in using biomarkers to develop precision medicine approaches to therapy including the post-COVID-19 long-haulers. A recent preprint of a meta-analysis suggests as many as 80% of individuals infected by COVID-19 may have at least one symptom long after infection." IncellDx, in collaboration with Ram Yogendra, MD, and Purvi Parikh, MD, launched the website on January 29, 2021.
Login Or Register To Read Full Story